HER2-directed antibody–drug conjugate composed of an anti-ERBB2 monoclonal antibody linked to a cytotoxic payload; binds HER2, is internalized, and releases the payload to kill HER2-expressing tumor cells with potential bystander effect.
HER2-directed antibody–drug conjugate: a humanized anti-ERBB2 monoclonal antibody linked via a cleavable linker to a camptothecin-derived topoisomerase I inhibitor. After binding HER2 and internalization, the linker is cleaved to release the payload, which stabilizes TOP1–DNA complexes, induces DNA breaks, blocks replication, and triggers apoptosis in HER2-expressing tumor cells, with potential bystander killing.
NO
INDIRECT
The ADC targets HER2 on the cell surface, is internalized, and releases a camptothecin-derived payload that inhibits TOP1, causing DNA damage and apoptosis; TOP1 is a downstream enzymatic target, not the targeting antigen.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
YES
DIRECT
ATG contains polyclonal antibodies that bind T-cell surface antigens including LFA-1 (CD18), leading to complement-dependent lysis, Fc-mediated ADCC, and phagocytic clearance of the bound cells.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
YES
DIRECT
Polyclonal ATG antibodies bind T-cell antigens (including CD25) and eliminate bound CD25+ cells via complement-dependent lysis, antibody-dependent cellular cytotoxicity, and opsonization/phagocytic clearance.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
YES
DIRECT
Polyclonal antibodies in ATG bind CD28 (and other T‑cell antigens) on T cells, triggering complement-dependent lysis and Fc-mediated ADCC/opsonophagocytosis, depleting CD28+ T cells.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
YES
DIRECT
ATG contains antibodies that bind CD45 on T cells, leading to complement-dependent lysis, antibody-dependent cellular cytotoxicity via FcγR-bearing effectors, and opsonization/phagocytic clearance.